viewShield Therapeutics PLC

Shield Therapeutics extends cash runway into 2021 after significant China deal

Proactive Research analyst Emma Ulker discusses Shield Therapeutics PLC's (LON:STX) 2019 business update and subsequent licence agreement for Feraccru/Accrufer with the integrated specialty pharma company Beijing Aosaikang Pharmaceutical Co Ltd (ASK Pharm) which covers China, Hong Kong, Macau and Taiwan. 

Ulker adds that a key highlight of 2019 included presentation of positive data from STX’s AEGIS head-to-head study of Feraccru vs the leading IV iron, Ferinject.

Click here to read Emma's note on Shield Therapeutics achieving significant milestones

Quick facts: Shield Therapeutics PLC

Price: 83.5 GBX

Market: LSE
Market Cap: £97.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Full interview: Shield Therapeutics 'seeking to conclude US partnering...

Shield Therapeutics PLC's (LON:STX) Tim Watts caught up with Proactive London's Andrew Scott to recap on the big events of 2019 as well as to update on how US partnering discussions are coming along. Shield ended the year with cash of £4.1mln, down from £9.8mln at the end of 2018. Following...

on 30/1/20

2 min read